{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:27:17Z","timestamp":1787113637288,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018887","name":"Roche Netherlands BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018887","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejca.2026.116882","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T18:45:09Z","timestamp":1781462709000},"page":"116882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7066-3129","authenticated-orcid":false,"given":"Fleur M.","family":"Louis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna van","family":"der Voort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mees D.","family":"Egeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette S.van","family":"Ramshorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6851-8731","authenticated-orcid":false,"given":"Ingrid AM","family":"Mandjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette J.","family":"Agterof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim A.van","family":"der Steeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan B.","family":"Heijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies L.van","family":"Bekkum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester JM","family":"Siemerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philomeen M.","family":"Kuijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Scholten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelle","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jeanne TFD Vrancken","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritse M.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonneke V.van","family":"de Poll-Franse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8088-9628","authenticated-orcid":false,"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116882_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Euro J Cancer"},{"key":"10.1016\/j.ejca.2026.116882_bib2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1078-0432.CCR-22-2829","article-title":"Survival Outcomes, Digital TILs, and On-treatment PET\/CT During Neoadjuvant Therapy for HER2-positive breast cancer: results from the randomized PREDIX HER2 Trial","volume":"29","author":"Matikas","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2026.116882_bib3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","volume":"403","author":"Perez-Garcia","year":"2024","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.ejca.2026.116882_bib4","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","article-title":"Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial","volume":"7","author":"van der Voort","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(24)00104-9","article-title":"MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study","volume":"25","author":"van der Voort","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib6","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116882_bib8","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.breast.2015.07.035","article-title":"Long term side effects of adjuvant chemotherapy in patients with early breast cancer","volume":"24","author":"Tao","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2026.116882_bib9","first-page":"709","article-title":"Early taxane exposure and neurotoxicity in breast cancer patients","volume":"32","author":"Cimbro","year":"2024","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2026.116882_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10549-022-06670-9","article-title":"Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study","volume":"195","author":"Engvall","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2026.116882_bib11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/annonc\/mdw099","article-title":"Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors","volume":"27","author":"Abrahams","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2021.12.001","article-title":"group P. Adverse health effects after breast cancer up to 14 years after diagnosis","volume":"61","author":"Heins","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2026.116882_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121896","article-title":"Long-Term Fatigue and Cognitive Disorders in Breast Cancer Survivors","volume":"11","author":"Joly","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116882_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1090326","article-title":"Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis","volume":"14","author":"Khoirunnisa","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejca.2026.116882_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(25)00707-7","article-title":"MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study","author":"Louis","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jamaoncol.2016.4851","article-title":"A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer: The International Consortium for Health Outcomes Measurement (ICHOM) Initiative","volume":"3","author":"Ong","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib17","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","article-title":"Chemotherapy de-escalation using an (18)F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","volume":"22","author":"P\u00e9rez-Garc\u00eda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib18","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1002\/cncr.32873","article-title":"Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer","volume":"126","author":"Conte","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116882_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.116882_bib21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.annonc.2019.10.027","article-title":"An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45","volume":"31","author":"Bjelic-Radisic","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib22","series-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.ejca.2026.116882_bib23","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ejca.2011.04.034","article-title":"The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts","volume":"47","author":"van de Poll-Franse","year":"2011","journal-title":"Eur J Cancer (Oxford England 1990)"},{"key":"10.1016\/j.ejca.2026.116882_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz037","article-title":"Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer","volume":"3","author":"Musoro","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ejca.2026.116882_bib25","doi-asserted-by":"crossref","first-page":"e499","DOI":"10.1016\/S1470-2045(25)00288-8","article-title":"Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer","volume":"26","author":"Tannock","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib26","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer (Oxford England 1990)"},{"key":"10.1016\/j.ejca.2026.116882_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2015.08.007","article-title":"Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust","volume":"69","author":"Giesinger","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2026.116882_bib28","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamaoncol.2023.0646","article-title":"Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive\/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial","volume":"9","author":"Gluz","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/SPC.0000000000000684","article-title":"Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy","volume":"18","author":"Hertz","year":"2024","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.ejca.2026.116882_bib30","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jamaoncol.2025.0001","article-title":"Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy: The POLAR Randomized Clinical Trial","volume":"11","author":"Michel","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types","volume":"188","author":"Musoro","year":"2023","journal-title":"Euro J Cancer"},{"key":"10.1016\/j.ejca.2026.116882_bib32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2025.43.16_suppl.501","article-title":"Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II\/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181\/CompassHER2 pCR trial","volume":"43","author":"Tung","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib33","first-page":"JCO2502176","article-title":"Neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in human epidermal growth factor receptor 2-positive breast cancer: the randomized noninferiority phase III neoCARHP Trial","author":"Gao","year":"2026","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(24)00581-3","article-title":"De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial","volume":"26","author":"Chen","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib35","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.1008054","article-title":"A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study","author":"Garrigos","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib36","unstructured":"Harbeck N., Modi S., Pusztai L., Ohno S., Wu J., Kim S.B., et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial\u2606. Annals of Oncology."},{"key":"10.1016\/j.ejca.2026.116882_bib37","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116882_bib38","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116882_bib39","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s11764-019-00793-7","article-title":"Cancer survivors who fully participate in the PROFILES registry have better health-related quality of life than those who drop out","volume":"13","author":"Ramsey","year":"2019","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.ejca.2026.116882_bib40","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","article-title":"Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer","volume":"22","author":"Franzoi","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:13:57Z","timestamp":1787112837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"alternative-id":["S0959804926006635"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116882","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116882"}}